Current knowledge of the multifunctional 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1)
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research (MOP 97917)
- Shanghai Science and Technology Committee, China (14JC1492300)
- National Institutes of Health (GM089820)
This publication has 84 references indexed in Scilit:
- Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factorJournal of Translational Medicine, 2013
- A New Nonestrogenic Steroidal Inhibitor of 17β-Hydroxysteroid Dehydrogenase Type I Blocks the Estrogen-Dependent Breast Cancer Tumor Growth Induced by EstroneMolecular Cancer Therapeutics, 2012
- 17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migrationBreast Cancer Research, 2012
- The Contribution of 17beta-Hydroxysteroid Dehydrogenase Type 1 to the Estradiol-Estrone Ratio in Estrogen-Sensitive Breast Cancer CellsPLOS ONE, 2012
- Sex steroid receptors in human lung diseasesThe Journal of Steroid Biochemistry and Molecular Biology, 2011
- Crucial Role of 3-Bromoethyl in Removing the Estrogenic Activity of 17β-HSD1 Inhibitor 16β-(m-Carbamoylbenzyl)estradiolACS Medicinal Chemistry Letters, 2011
- Insights in 17β-HSD1 Enzyme Kinetics and Ligand Binding by Dynamic Motion InvestigationPLOS ONE, 2010
- Novel Hydroxysteroid (17β) Dehydrogenase 1 Inhibitors Reverse Estrogen-Induced Endometrial Hyperplasia in Transgenic MiceThe American Journal of Pathology, 2010
- Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation SetCancer Epidemiology, Biomarkers & Prevention, 2007
- Genetic Variation in the HSD17B1 Gene and Risk of Prostate CancerPLOS Genetics, 2005